Types and clinical use of anti-TGF-β/TGF-βR targeted therapies
| Drug | Type, target and refs | Disease, stage and refs |
|---|---|---|
| Fresolimumab/GC-1008 | mAb against TGF-β1,-2,-365 | Breast cancer (with radiotherapy, Phase I), RCC and malignant melanoma (Phase II)65 66 |
| Trabedersen/AP12009 | ASO against TGF-β1 mRNA53 | CRC, pancreatic carcinoma and malignant melanoma, NSCLC (Phase I/II)53 |
| Belagenpumatucel-L/Lucanix; | ASO (antisense gene-modified allogeneic tumour cell vaccine) against TGF-β2 mRNA53 66 | NSCLC (Phase II)67 |
| LY2157299 | TGFβR1 serine/threonine kinase inhibitor68 | HCC (Phase II), pancreatic cancer (with gemcitabine, Phase I/II)66 68 |
ASO, antisense oligonucleotides; CRC, colorectal carcinoma; HCC, hepatocellular carcinoma; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; TGF-β, transforming growth factor-β; mAb, monoclonal antibody.